Keywords

• ABT-199
• ABT199
• 99% purity

Quick Details

• ProName: Venetoclax, ABT-199, ABT199, GDC-0199,...
• CasNo: 1257044-40-8
• Molecular Formula: C45H50ClN7O7S
• Appearance: yellow powder
• Application: just for experiment
• DeliveryTime: 1 month
• Port: shanghai
• ProductionCapacity: 1000 Gram/Month
• Purity: 99%
• Storage: -20℃ for 3 years
• LimitNum: 1 Gram

Superiority

We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.

We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.

We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.

We make our efforts to offer customer innovative, customized, high-quality service.

Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.

Details

ABT-199 (GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1.
IC50 Value: <0.01 nM (Ki)
Target: Bcl-2 selective
ABT-199 is a potent and selective inhibitor of B-cell lymphoma-2 (BCL-2) family proteins, currently in clinical trials. ABT-199 inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers.